

**Supplementary Table 2.** Demographics and clinicopathologic characteristics of patients between groups N0 and A

Characteristic	Group N0 (n = 56)	Group A (n = 21)	P-value
Age (yr)			0.445
≤60	35 (62.5)	11 (52.4)	
>60	21 (37.5)	10 (47.6)	
Sex			0.079
Male	29 (51.8)	6 (28.6)	
Female	27 (48.2)	15 (71.4)	
Hemoglobin (g/L)			0.799
≤130	29 (51.8)	12 (57.1)	
>130	27 (48.2)	9 (42.9)	
Serum albumin (g/L)			>0.999
≤35	5 (8.9)	2 (9.5)	
>35	51 (91.1)	19 (90.5)	
TBIL (μmol/L)			0.581
≤17.1	37 (66.1)	16 (76.2)	
>17.1	19 (33.9)	5 (23.8)	
ALT (U/L)			0.430
≤40	33 (58.9)	15 (71.4)	
>40	23 (41.1)	6 (28.6)	
γ-GT (U/L)			0.096
≤50	13 (23.2)	1 (4.8)	
>50	43 (76.8)	20 (95.2)	
PT (sec)			0.474
≤14	55 (98.2)	20 (95.2)	
>14	1 (1.8)	1 (4.8)	
INR			>0.999
≤1.15	54 (96.4)	20 (95.2)	
>1.15	2 (3.6)	1 (4.8)	
HBsAg			0.764
Negative	41 (73.2)	17 (81.0)	
Positive	14 (25.0)	4 (19.0)	
Missing	1 (1.8)	0 (0)	
CEA (μg/L)			0.417
≤5	39 (69.6)	12 (57.1)	
>5	17 (30.4)	9 (42.9)	
CA 125 (U/mL)			0.100
≤35	43 (76.8)	12 (57.1)	
>35	13 (23.2)	9 (42.9)	
CA 19-9 (U/mL)			0.787
≤35	19 (33.9)	6 (28.6)	
>35	37 (66.1)	15 (71.4)	
Tumor number			0.060
1	44 (78.6)	12 (57.1)	
>1	9 (16.1)	8 (38.1)	
Missing	3 (5.3)	1 (4.8)	
Tumor size (cm)			0.604
≤5	25 (44.6)	8 (38.1)	
>5	27 (48.2)	12 (57.1)	
Missing	4 (7.2)	1 (4.8)	
Tumor type			0.322
Non-mass-forming	7 (12.5)	1 (4.76)	
Mass-forming	49 (87.5)	20 (95.2)	
Surgical margin			0.706
R0	52 (92.9)	20 (95.2)	
R1	4 (7.1)	1 (4.8)	
No. of LNs harvested			0.010
<6	37 (66.1)	7 (33.3)	
≥6	19 (33.9)	14 (66.7)	

**Supplementary Table 2.** Continued

Characteristic	Group N0 (n = 56)	Group A (n = 21)	P-value
Vascular invasion			>0.999
No	43 (76.8)	16 (76.2)	
Yes	10 (17.9)	3 (14.3)	
Missing	3 (5.3)	2 (9.5)	
Surgery time (min)			>0.999
≤300	36 (64.3)	14 (66.7)	
>300	20 (35.7)	7 (33.3)	
Blood loss (mL)			>0.999
≤300	32 (57.1)	12 (57.1)	
>300	24 (42.9)	9 (42.9)	
Blood transfusion			0.790
No	39 (69.6)	14 (66.7)	
Yes	17 (30.4)	7 (33.3)	
Postoperative hospital stay (day)			>0.999
≤12	35 (62.5)	13 (61.9)	
>12	21 (37.5)	8 (38.1)	
Postoperative complication			0.695
No	43 (76.8)	17 (81.0)	
Yes	13 (23.2)	4 (19.1)	
Adjuvant treatment			0.509
No	53 (94.6)	19 (90.5)	
Yes	3 (5.4)	2 (9.5)	

Values are presented as number (%).

TBIL, total bilirubin; INR, international normalized ratio; LN, lymph node.